Mydecine Innovations Group Company Information
|Name||Mydecine Innovations Group|
|Industry||Drug Manufacturers—Specialty & Generic|
|Headquarters||Suite 810 – 789 West Pender Street |
Vancouver, BC, V6C 1H2, Canada
Mydecine Innovations Group is a leading company in the life sciences category specializing in digital health solutions, research and development, and natural health products focusing on fungi.
The brand consists of three companies, namely Mindleap health, Neropharm, and Mydecine Health Sciences. Each company utilizes its core strength and builds its vertical focus to position itself as a market leader. When integrated, the companies become a giant entity with a huge impact and output in the industry.
The company aims at providing millions of people around the world with unconventional, effective, innovative, safe, and functional medical alternatives that improve their quality of life.
Mydecine is a vertically integrated company that consists of a team of dynamic, functional, and dedicated industry experts who oversee the entire medicine development process:
- Intricate genetic research
- Clinical trials
- Delivery systems
- Import or export of products
- Commercialization of the products
- The distribution process
The brand has positioned itself as a leader in the production and distribution of psychedelics to treat mental conditions worldwide. It is involved in the research and development of:
- Naturally psychedelic-assisted psychotherapy
- Novel compounds
- Therapy protocols
- Unique and proprietary delivery systems
The company has access to a Canada Health-approved world-class cGMP certified facility that it utilizes in the cultivation, extraction, and analysis of mushroom compounds. It also has a top-of-the-line mycology laboratory located in Denver that deals with non-psychedelic medicinal mushrooms.
The company believes that with the considerable evidence supporting the effectiveness of psychedelic-assisted psychotherapy, this approach will continue receiving worldwide acceptance.
As a result, Mydecine is focused on maintaining its leading role in technology, clinical trials, research, and global supply.
Mydecine’s Scientific Advisory Board
Mydecine’s SAB comprises an elite group of science-oriented professionals from the R&D, academic, military, and corporate worlds. The team members are pulled from its numerous branches across states.
The SAB’s members are accomplished in their respective fields, making immense contributions towards the advancement of psychedelic medicine. Together, they aim to push Mydecine’s mission further through;
- Offer vital support in PTSD clinical trials by giving direction and guidance on the best strategies to implement.
- Advice the company on intellectual property
- Provide their professional opinions and advice on the company’s Mindleap Health (Telehealth platform)
Mydecine ‘s portfolio
Natural health products
Mushroom species go beyond 50,000, and each has its own unique variety of compounds that provide numerous therapeutic benefits. Many of the compounds have been discovered, but some remain under-studied.
The team at Mydecine is looking into these compounds to make fungtional mushroom products and psychedelic medicine.
Research and development
Mydecine’s research and development team is determined to build a wealth of resources to unleash fungi’s potential in promoting human wellness. They focus on commercializing psilocybin medicine and fungitional mushrooms.
Digital health solutions
The company is focused on creating state-of-the-art technology that solves the mental health crisis on a global scale. They aim to achieve this through Mindleap, a digital platform that combines three vital areas: digital therapeutics, psychedelic-derived drugs, and quantified mental health.
The platform was designed to help millions of individuals suffering from various mental health conditions by providing a robust set of tools.